BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Bone cancer AND MAPK1, MAPK2, 5594, ENSG00000100030, P28482, ERK2, p40, PRKM1, p38, p41, ERT1, p41mapk, PRKM2, P42MAPK, ERK AND Staging
6 results:

  • 1. Histiocytic cell neoplasms involving the bone marrow: summary of the workshop cases submitted to the 18th Meeting of the European Association for Haematopathology (EAHP) organized by the European bone Marrow Working Group, Basel 2016.
    Tzankov A; Kremer M; Leguit R; Orazi A; van der Walt J; Gianelli U; Hebeda KM
    Ann Hematol; 2018 Nov; 97(11):2117-2128. PubMed ID: 30084011
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Poorly Differentiated Nonkeratinizing Squamous Cell Carcinoma of the Thymus: Clinicopathologic and Molecular Genetic Study of 25 Cases.
    Suster D; Pihan G; Mackinnon AC; Suster S
    Am J Surg Pathol; 2018 Sep; 42(9):1224-1236. PubMed ID: 29975245
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. High Expression of Phosphorylated Extracellular Signal-Regulated Kinase (erk1/2) is Associated with Poor Prognosis in Newly Diagnosed Patients with Multiple Myeloma.
    Fan L; Hong J; Huang H; Fu D; Wu S; Wang Q; Ye Y; Liu Y
    Med Sci Monit; 2017 May; 23():2636-2643. PubMed ID: 28557972
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. CD200 expression in patients with Multiple Myeloma: another piece of the puzzle.
    Conticello C; Giuffrida R; Parrinello N; Buccheri S; Adamo L; Sciuto MR; Colarossi C; Aiello E; Chiarenza A; Romano A; Salomone E; Gulisano M; Giustolisi R; Di Raimondo F
    Leuk Res; 2013 Dec; 37(12):1616-21. PubMed ID: 24183830
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia.
    Roccaro AM; Sacco A; Chen C; Runnels J; Leleu X; Azab F; Azab AK; Jia X; Ngo HT; Melhem MR; Burwick N; Varticovski L; Novina CD; Rollins BJ; Anderson KC; Ghobrial IM
    Blood; 2009 Apr; 113(18):4391-402. PubMed ID: 19074725
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. PD 098059, an inhibitor of erk1 activation, attenuates the in vivo invasiveness of head and neck squamous cell carcinoma.
    Simon C; Hicks MJ; Nemechek AJ; Mehta R; O'Malley BW; Goepfert H; Flaitz CM; Boyd D
    Br J Cancer; 1999 Jul; 80(9):1412-9. PubMed ID: 10424744
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.